Lilly
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Alchemab Therapeutics
9 Sept 2025
Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform
Alchemab identifies naturally occurring protective antibodies using AI and patient data, developing new therapies based on disease resilience rather than traditional target discovery.
Laverock Therapeutics
1 Jul 2025
Laverock Therapeutics raises over £20m in expanded seed round led by Calculus Capital to advance gene control therapies
Laverock Therapeutics is developing programmable gene control technologies that enable advanced therapies to respond dynamically to disease, improving precision, safety and effectiveness in cell-based treatments.
Maxion Therapeutics
17 Mar 2025
Maxion Therapeutics raises £58m in Series A led by General Catalyst to advance KnotBody pipeline
Maxion Therapeutics develops antibody-based KnotBody drugs targeting ion channels and GPCRs, advancing new treatments for inflammatory, pain and cardiovascular diseases with improved selectivity.
Lilly
- 3(12 months)
- lilly.com/uk
- Update Information
More venture news
- 12 Nov 2024
OoodlesIT procurement fintech Ooodles raises £2m in further funding as it expands to the Irish market
Follow-onFintech - 28 Apr 2025
WorkBuzzWorkBuzz raises £4m follow-on led by YFM Equity Partners to scale AI-driven employee engagement platform
Follow-onHR - 6 Aug 2025
Wanda HealthWanda Health raises £830k in follow-on funding led by EMV Capital to scale virtual care and RPM platform across the US
Follow-onHealth
